Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06138873 · ClinicalTrials.gov registry record · NA

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

A NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy, sponsored by Rush University Medical Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
5
Study locations

NCT06138873: Recruiting NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy, sponsored by Rush University Medical Center.

NCT06138873 is a NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 100 participants, below the 285-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06138873, a NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy, is actively recruiting participants, sponsored by Rush University Medical Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
5
Study locations

Study Summary

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.

Primary Outcome

Percentage of reduction in ablation time in seconds, with ablation time defined as the total radiofrequency delivery time delivered during the VT ablation procedure. Total ablation time is automatically recorded by the Carto System Software and will be subsequently extracted as part of a raw unedited data file for unbiased endpoint evaluation.

Conditions Studied

Ventricular Tachycardia Ischemic Cardiomyopathy

Interventions

  • PROCEDURE Ablation-index guided ventricular tachycardia ablation
  • PROCEDURE Ventricular tachycardia ablation with no AI-guidance

Study Locations (5)

Illinois

  • Rush University Medical Center - Chicago

Massachusetts

  • Mass General Brigham and Women's Hospital - Boston

Michigan

  • Medical University of Michigan - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-10-23
Est. Completion 2027-11-23
Phase NA
Rush University Medical Center

320 total trials

What NCT06138873 shows while recruiting

NCT06138873 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 285-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (65% lower).

The record links to 2 conditions, with Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Ablation-index guided ventricular tachycardia ablation is the first listed.

NCT06138873 lists 5 locations in 5 states (Illinois, Massachusetts, Michigan).

Frequently Asked Questions

What is clinical trial NCT06138873 about?

NCT06138873 is a clinical study titled "Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy". Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality h...

What is the current status of trial NCT06138873?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-10-23. Estimated completion is 2027-11-23.

What conditions does trial NCT06138873 study?

This clinical trial studies the following conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy.

What interventions are being tested in trial NCT06138873?

The interventions under investigation include: Ablation-index guided ventricular tachycardia ablation (PROCEDURE), Ventricular tachycardia ablation with no AI-guidance (PROCEDURE).

Who is sponsoring clinical trial NCT06138873?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06138873 being conducted?

This trial has 5 study locations across Illinois, Massachusetts, Michigan, Minnesota, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ventricular Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06138873's enrollment target sits among peer trials

100 16th of 28 higher than 12 of 28 other Ventricular Tachycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ventricular Tachycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06138873

Source: ClinicalTrials.gov NCT06138873, the US trial registry maintained by the National Library of Medicine. NCT06138873 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.